TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meets protocol-specified criteria for qualification and contraception~* Willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* History or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff;~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine 0.5 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
- Buprenorphine 0.25 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
- Buprenorphine 0.125 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo-matching buprenorphine sublingual spray TID for two days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ≥ 18 years~* Subjects who have received oral vitamin K-antagonist therapy~* Subjects who have acute major bleeding, defined as one of the following: life-threatening or potentially life-threatening, acute bleeding associated with a fall in hemoglobin (Hb) level ≥ 2g/dL, bleeding requiring blood product transfusion~* INR ≥ 2 within 3 hours before start of study treatment~* Informed consent has been obtained~Exclusion Criteria:~* Expected survival of less than 3 days, or expected surgery in less than 1 day~* Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control the acute bleeding event~* Use of unfractionated or low molecular weight heparin use from 24 hours prior to enrollment or expected need within 24 hours after start of infusion~* For patients with ICH: Glasgow coma score (GCS) \< 7; intracerebral hematoma volume \> 30cc as assessed by ABC/21; for subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm; for subarachnoid hemorrhage: any evidence of hydrocephalus; infratentorial ICH location; epidural hematomas; intraventricular extension of hemorrhage; modified Rankin score (mRS) of \>3 prior to ICH~* History of thrombotic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within 3 months of enrollment~* Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies~* Suspected or confirmed sepsis at time of enrollment~* Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study~* Large blood vessel rupture (e.g. in advanced cancer patient)~* Pre-existing progressive fatal disease with a life expectancy of less than 2 months~* Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia~* Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study~* Presence or history of hypersensitivity to components of the study medication~* Pregnant or breast-feeding women~* Prior inclusion in this study or any other CSL Behring-sponsored Beriplex study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beriplex® P/N (Type: EXPERIMENTAL): None
- Fresh frozen plasma (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically (histologically) proven diagnosis of non-muscle invasive (Ta, Tis or T1) bladder cancer~* In their treating physician's opinion is a good candidate for BCG therapy~* Be able to give informed consent~* Be age 18 or older~* Not be in an immunosuppressed state (e.g. HIV, use of chronic steroids)~* Not have active, uncontrolled infections~* Not be on agents known to alter rapamycin metabolism significantly~* Not have a reported history of liver disease (e.g. cirrhosis)~* Not have a prior history of non-bladder cancer unless the cancer is clinically stable and not requiring active treatment except basal cell carcinoma or squamous cell carcinoma of the skin.~* Not pregnant, or taking effective contraception before rapamycin therapy, during therapy and for 12 weeks after discontinuation of therapy.~Exclusion Criteria:~* Have muscle-invasive (≥T2) bladder cancer~* Unable to give informed consent~* Age \< 18~* Immunosuppressed state (e.g. HIV, use of chronic steroids)~* Active, uncontrolled infections~* On agents known to alter rapamycin metabolism significantly~* Another cancer requiring active treatment (except basal cell carcinoma or squamous cell carcinoma of the skin)~* Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy.~* Individuals with a reported history of liver disease (e.g. cirrhosis)~* Individuals who are not a good candidate for BCG in their treating physician's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rapamycin 0.5mg (Type: ACTIVE_COMPARATOR): Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
- Rapamycin 2.0mg (Type: ACTIVE_COMPARATOR): Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
- Control (Type: NO_INTERVENTION): Subject will be apart of the control group and won't take the study drug being tested

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin as a Treatment for Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PAH or PAH related to collagen vascular disease~* Age 18 years or over~* Receiving conventional therapy with diuretics, digoxin, warfarin, sildenafil and bosentan. Stable for 1 month~* 6 minute walk distance between 150m and 450m~* Modified NYHA functional class II or III~Exclusion Criteria:~* PAH from a cause other than permitted by entry criteria~* Change in PAH treatment in past 4 weeks~* Patients requiring prostanoid therapy~* Patients already taking a statin~* Clinically significant disturbance of liver function - AST or ALT \>3xULM; bilirubin \>1.5xULM~* Contraindication for a magnetic resonance scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Control (Type: PLACEBO_COMPARATOR): Placebo tablet once daily
- Arm 2: Experimental (Type: EXPERIMENTAL): Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Lappa Arctium (Homoeopathic Medicine) in Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 12 to 25 years of age~* Presence of inflammatory and non-inflammatory lesions~* Able to follow-up according to protocol~* Patients not taking any medication for treatment of Acne in preceding one month.~Exclusion Criteria:~* Acne Conglobata~* Pregnant or Breast feeding females or females having intention of becoming pregnant~* Significant systemic disease~* Any drug/ alcohol addiction~* History of chronic diseases treated with medications in the preceding month which might affect acne condition and treatment outcome

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* have a primary diagnosis of schizophrenia or schizoaffective disorder based on International Classification of Diseases (10th edition);~* under antipsychotic medications for at least three months and current conditions are stable, indicated by no difficulty to communicate with investigators and give informed consent;~* have developed at least one overt hyperPRL-associated symptom, including oligomenorrhoea (infrequent, irregularly timed episodes of bleeding occurring at intervals of more than 35 days from the previous menstrual cycle), amenorrhoea (the absence of menstruation for three menstrual cycles or 6 months), galactorrhea, decreased libido, anorgasmia or erectile dysfunction; and~* serum PRL levels are \>24 ng/ml (or 1043.472 pmol/l) in female or \>19 ng/ml (or 826.082 pmol/l) in male.~Exclusion Criteria:~* unstable medical conditions;~* suicidal ideas or attempts or aggressive behavior;~* history of alcoholism in the past one year, characterized by compulsive and uncontrolled consumption of alcohol, despite the realization of its negative effects on health, relationship, and social standing;~* history of drug abuse in past one year;~* currently treated with Chinese medicine or other natural products;~* allergic history of herbal medicine;~* pre-existing hyperPRL symptoms not associated with antipsychotic treatment; and~* pregnant and lactating women and those who refuse to use contraception during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PGD granules (Type: ACTIVE_COMPARATOR): While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-65 years old~* Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.~* Treatment history of an inadequate response to at least one and no more than three antidepressants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: PLACEBO_COMPARATOR): None
- A2 (Type: ACTIVE_COMPARATOR): None
- A3 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~Inclusion_Criteria:~* Male and female patients with a diagnosis of type 2 diabetes mellitus and previo usly treated with metformin alone or with metformin and one other oral antidiabetic d rug~* HbA1c 7.0 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug~* HbA1c 7.5 10.0% at screening for patients treated with metformin alone~* HbA1c 7.5 10.0% at beginning of the placebo run-in phase~* Age \> 21 and \< 75 years~* MI \> 25 and \< 40 kg/m2 (Body Mass Index)~Exclusion criteria:~Exclusion_Criteria:~* Clinically relevant cardiovascular disease~* Impaired hepatic function~* Renal insufficiency or impaired renal function~* Treatment with rosiglitazone or pioglitazone within 6 months prior to screening~* Treatment with insulin within 3 months prior to screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin low dose (Type: EXPERIMENTAL): Patients receive Linagliptin low dose tablets once daily
- Linagliptin medium dose (Type: EXPERIMENTAL): Patients receive Linagliptin medium dose tablets once daily
- Linagliptin high dose (Type: EXPERIMENTAL): Patients receive Linagliptin high dose tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive tablets identical to those containing Linagliptin low, medium and high dose
- Glimepiride (Type: ACTIVE_COMPARATOR): Patients receive Glimepiride tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the trial laboratory.~* Participants with one of the following pulmonary TB conditions:~DS-TB treatment arm participants should be:~* sensitive to rifampicin and isoniazid by rapid sputum based test AND~* either newly diagnosed for TB or have a history of being untreated for at least 3 years after cure from a previous episode of TB.~DR-TB treatment arm participants should be Resistant to rifampicin and/or isoniazid.~* Of non-childbearing potential or willing to practice effective methods of birth control~* Body weight (in light clothing and no shoes) ≥ 30 kg.~* Completed informed consent form~Exclusion Criteria:~* Karnofsky score \<60%~* Any risk factor for QT prolongation~* Any planned contraindicated medicines~* Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests).~Any of the following lab toxicities/abnormalities:~* CD4+ count \< 100 cells/µL (HIV infected participants)~* platelets \<75,000/mm³~* creatinine \>1.5 times upper limit of normal (ULN)~* eGFR ≤ 60 mL/min~* haemoglobin \<8.0 g/dL~* serum potassium less than the lower limit of normal for the laboratory.~* GGT: greater than 3 x ULN~* AST: ≥3.0 x ULN to be excluded;~* ALT: ≥3.0 x ULN to be excluded~* ALP: ≥3.0 x ULN to be excluded~* Total bilirubin: \>1.5 x ULN to be excluded;~* Direct bilirubin: greater than 1x ULN to be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Sensitive BPaMZ (Type: EXPERIMENTAL): Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
- Drug Sensitive Standard Treatment (Type: ACTIVE_COMPARATOR): isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
- Drug Resistant BPaMZ (Type: EXPERIMENTAL): Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization~* At least one of the following signs or symptoms of bacteremia:~  1. fever (e.g.≥ 38 °C/100.4 °F measured orally)~ 2. white blood cell count \> 10,000 or \< 4,000 cells/µL, or \> 10% immature neutrophils (bands)~ 3. tachycardia (heart rate \> 90 bpm)~ 4. hypotension (systolic blood pressure \< 90 mmHg)~* At least one of the following:~  1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis~ 2. Persistent SAB~ 3. Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria~ 4. Other forms of complicated SAB~ 5. Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)~ 6. Epidural or cerebral abscess~* Other inclusion criteria have been applied~Exclusion Criteria:~* Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance~* Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam~* Left-sided infective endocarditis~* Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices~* Community- or hospital-acquired pneumonia~* Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active~* Requirement for continuous renal-replacement therapy~* Women who are pregnant or nursing~* Other exclusion criteria have been applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)
- Daptomycin (Type: ACTIVE_COMPARATOR): Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016).~* Should have failed at least 1 line of prior therapy (defined as failure to respond to therapy, and/or progression during or after therapy).~* Should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.~* Should have adequate hematologic, kidney and liver function as described in the protocol.~* For participants enrolling into the Expansion Cohort only: a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol.~Exclusion Criteria:~* Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.~* Has a history of other malignancies within 2 years prior to study entry, with exceptions as described in the protocol.~* Has active central nervous system leukemia.~* Has a history of chronic New York Heart Association (NYHA) class IV heart failure.~* Has a corrected QT interval of \> 450 ms.~* Has a chronic respiratory disease that requires continuous oxygen use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation Venetoclax + Gilteritinib (Type: EXPERIMENTAL): Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
- Dose Expansion Venetoclax + Gilteritinib (Type: EXPERIMENTAL): Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete